Recently, the fully human anti-CD47 IgG4 antibody TJC4 (TJ011133) was shown to specifically block the CD47-SIRPα axis, enhancing phagocytosis in a set of tumour cell lines and AML primary cells. This evidence concerns the gene CD47 and acute myeloid leukemia.